<DOC>
	<DOCNO>NCT00448591</DOCNO>
	<brief_summary>This single arm study assess safety efficacy regimen Avastin plus taxane , without additional chemotherapy , first-line treatment patient locally recurrent metastatic breast cancer . All patient receive Avastin ( 10mg/kg iv every 2 week , 15 mg/kg iv every 3 week ) plus taxane-based chemotherapy . If taxanes contraindicate , alternative chemotherapy ( anthracyclines pegylated liposomal doxorubicin ) may use . The anticipated time study treatment disease progression , target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Plus Taxane-Based Therapy Patients With Locally Recurrent Metastatic Breast Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>patient , &gt; =18 year age ; HER2 negative adenocarcinoma breast , locally recurrent metastatic disease ; ( HER2 positive patient previously treat Herceptin adjuvant setting ; candidate chemotherapy . previous chemotherapy metastatic locally recurrent breast cancer ; concomitant hormonal therapy metastatic locally recurrent disease ; concomitant Herceptin therapy treatment metastatic locally recurrent HER2 positive disease ; previous radiotherapy treatment metastatic disease ; evidence CNS metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>